1. "Pergamon-Elsevier Science Ltd"
  2. "2006"
Formats
  1. Journal Article (14)
  2. Meeting Abstract (11)
Groups
  1. Molecular Pharmacology and Chemistry Program Faculty (18)
  2. Sloan Kettering Institute Faculty (18)
  3. Department of Medicine (9)
  4. GSK Faculty (9)
  5. Solid Tumor Oncology Division (7)
  6. Breast Medicine Service (6)

More Groups

People
  1. Samuel Danishefsky (9)
  2. Bin Wu (5)
  3. Gong Chen (5)
  4. Jiehao Chen (5)
  5. David Solit (4)
  6. Neal Rosen (4)

More People

Years
  1. 2006 (25)
Publications
  1. EJC Supplements (12)
  2. Tetrahedron Letters (8)
  3. Bioorganic & Medicinal Chemistry Letters (2)
  4. Applied Radiation and Isotopes (1)
  5. Bioorganic & Medicinal Chemistry (1)
  6. Heterocycles (1)
Publishers
  1. Pergamon-Elsevier Science Ltd (25)

Results (25)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety of Volociximab as a monotherapy and in combination with chemotherapy the result of three phase II studies
    Meeting Abstract

    Yazji, S.; Figlin, R. A.; Kirkwood, J. M.; Valle, J. W.; Ramanathan, R. K.; Bukowski, R. M.; Bedikian, A. Y.; Cranmer, L. D.; Kondagunta, G. V.; Evans, J.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Combined inhibition of PI3K/AKT and MAPK signaling is required to inhibit translational initiation and to induce apoptosis in human tumors
    Meeting Abstract

    She, Q. B.; Ye, Q.; Solit, D.; Rosen, N.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • TGF beta pathway imaging in metastases
    Meeting Abstract

    Serganova, I.; Blasberg, R.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Inhibition of Hsp90 function downregulates EGFR and sensitizes EGFR-mutant xenografts to paclitaxel
    Meeting Abstract

    Sawai, A.; Greulich, H.; Ye, Q.; Sellers, W.; Rosen, N.; Solit, D.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • B-RAF mutation is associated with altered patterns of negative feedback of MAPK signaling that correlate with increased output of the pathway and increased sensitivity to MEK inhibition
    Meeting Abstract

    Pratilas, C.; Grbovic, O.; Zhao, H.; Viale, A.; Solit, D.; Rosen, N.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Early phase experience with pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate with high affinity for the reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies
    Meeting Abstract

    O'connor, O.; Hamlin, P.; Neylon, E.; Moskowitz, C.; Portlock, C.; Noy, A.; Sirotnak, F.; Zelenetz, A.; Mould, D.; Horwitz, S.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Correlative results of in-vivo monitoring of platelet-derived growth factor receptor (PDGFR) activation status in a randomized placebo-controlled trial of docetaxel +/- imatinib in castration-resistant prostate cancer (CRPC) and bone metastases (BM)
    Meeting Abstract

    Mathew, P.; Thall, P. F.; Wen, S.; Horne, E.; Johnson, M.; Oh, W. K.; Morris, M. J.; Logothetis, C. J.; Fidler, I. J.; Bucana, C.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Decline in serum HER-2/neu predicts response to trastuzumab-based therapy
    Meeting Abstract

    Leitzel, K.; Esteva, F.; Fornier, M.; Gligorov, J.; Harris, L.; Kostler, W.; Luftner, D.; Pichon, M.; Tse, C.; Lipton, A.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Defining Hsp90 as inhibitor of apoptosis in small cell lung cancer
    Meeting Abstract

    Chiosis, G.; Rodina, A.; Kim, J.; Aguirre, J.; Moulick, K.; Lopes, E. C.; Wu, N.; She, Y.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • SNX5542, an oral Hsp90 inhibitor, causes Her2 degradation and inhibition of tumor growth in models of Her2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Ye, Q.; Huang, K.; Fadden, P.; Rosen, N.; Solit, D.
    EJC Supplements (2006)

    Fulltext@MSK | Save